Viral Conjunctivitis Pipeline Drugs Market Report

Viral Conjunctivitis Pipeline Drugs Market Analysis by Pipeline Drugs (FST-100 (2020-2023), By APD- 209 (2021-2023), Early Stage Preclinical Trials (Tabular Format)), 2014 To 2025

Format: PDF  |  Report ID: GVR4342

Viral Conjunctivitis also known as “pinkeye”. It is a highly contagious acute conjunctival infection usually caused by adenovirus. Some of the other viruses that can cause conjunctival infection consist of herpes simplex virus (HSV), varicella-zoster virus (VZV), picornavirus (enterovirus 70, Coxsackie A24), poxvirus (molluscumcontagiosum, vaccinia), etc. Some of the signs and symptoms of viral conjunctivitis include light sensitivity, tearing, itchy eyes, redness, etc.

Patients suffering from viral conjunctivitis should avoid touching their eyes, sharing towels, napkins, pillow cases, etc. Additionally, the transmission may also occur through accidental inoculation of viral particles from patient’s hands, contaminated swimming pools as well as by contact from droplets of infected upper respiratory tracks.

The factors that propel the growth of the global Viral Conjunctivitis Pipeline Drugs Market include accessibility of diagnostic test, increasing healthcare expenditure, rising awareness, and increased R&D activities. Viral Conjunctivitis is one of the major causes of infectious conjunctivitis consequently increasing the need for viral conjunctivitis pipeline drugs. The occurrence rate of viral conjunctivitis is greater in some regions like Brazil, Japan, etc. but there are no effective permitted drugs; which thereby propel the growth of global Viral Conjunctivitis Pipeline Drugs Market.

On the other hand, there are also factors that hamper the growth of the global Viral Conjunctivitis Pipeline Drugs Market such as high cost, appropriate diagnosis, and less awareness regarding advance technologies. Furthermore, most of the conjunctivitis is the consequence of enteroviruses and adenoviruses that are self-limiting in most conditions and can be resolved within seven to ten days.

The global Viral Conjunctivitis Pipeline Drugs Market is classified on the basis of pipeline drug and country. On the basis of pipeline drug, the global Viral Conjunctivitis Pipeline Drugs Market is classified as FST-100, APD- 209, and Early Stage Preclinical Trials (Tabular Format).

The key viral conjunctivitis drugs in the pipeline are APD-209 and FST-100. In case of these two viral conjunctivitis drugs, FST-100 is expected to account for the major share in the market. Foresight Biotherapeutics Inc. originated the development of treatment and therapies in ophthalmology and otolaryngology such as the FST-100. At present, the APD-209 is experiencing moderate growth rate. Nevertheless, it will account for higher demand in the coming years as compared to that of FST-100. Adenovir Pharma AB is the company to develop APD-209 and is undergoing phase II clinical trial.

On the basis of country, the global Viral Conjunctivitis Pipeline Drugs Market is classified as U.S., England, Germany, Australia, Japan, and Brazil.

In case of geographical region, U.S. holds a major share of the global Viral Conjunctivitis Pipeline Drugs Market. The factors that attribute to the major share include large patient pool diagnosed of viral conjunctivitis, more awareness regarding inappropriate utility of antibiotics, ongoing promising clinical trials, and accessibility & amplified application of diagnostic tests.

Moreover, not even one drug has been sanctioned by the U.S. FDA as of now. Therefore, promotion of novel drugs is projected to enhance the market growth during the forecast period. Approximately millions of people in the U.S. are affected every year by acute conjunctivitis. Presently, in the U.S. FST-100 and APD-209 are in early phase clinical trials and are expected to be launched in the upcoming years.

Some of the prominent players that fuel the growth of the global Viral Conjunctivitis Pipeline Drugs Market include Adenovir Pharma AB, Allergan plc, NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc., Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA